Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Clinical trial NCT05125302 · RECRUITING
Trial details
- NCT number
- NCT05125302
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-13
- Primary completion
- 2027-05-01
- Enrollment
- 1059
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.